Tang Faqing, Yang Zongbei, Tan Yuan, Li Yuejin
1Department of Clinical Laboratory, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, 410013 Changsha, China.
2Department of Clinical Laboratory, Zhuhai People's Hospital & Zhuhai Hospital of Jinan University, 519000 Zhuhai, China.
NPJ Precis Oncol. 2020 Feb 12;4:2. doi: 10.1038/s41698-020-0108-z. eCollection 2020.
Recently, super-enhancers (SEs) have been identified as a unique type of transcriptional regulation involved in cancer development. SEs exhibit a size, high transcription factor density, and strong binding to the transcriptional machinery compared with typical enhancers. SEs play an essential role in cell growth, differentiation, and disease initiation and progression including tumorigenesis. In particular, cancer-specific SEs have been proven to be key oncogenic drivers types of tumor cells. Furthermore, it has been confirmed that cancer-specific SEs can mediate the dysregulation of signaling pathways and promote cancer cell growth. Additionally, therapeutic strategies directly targeting SE components, for example, by disrupting SE structure or inhibiting SE cofactors, have shown a good curative effect on various cancers.
最近,超级增强子(SEs)已被确定为一种参与癌症发展的独特转录调控类型。与典型增强子相比,SEs具有较大的尺寸、高转录因子密度以及与转录机制的强结合力。SEs在细胞生长、分化以及包括肿瘤发生在内的疾病起始和进展中发挥着至关重要的作用。特别是,癌症特异性SEs已被证明是肿瘤细胞的关键致癌驱动因素。此外,已经证实癌症特异性SEs可介导信号通路的失调并促进癌细胞生长。此外,直接靶向SE成分的治疗策略,例如通过破坏SE结构或抑制SE辅因子,已在各种癌症中显示出良好的治疗效果。